Steglatro (Ertugliflozin)

Save over 65% on brand name Steglatro from the UK.

Prescription Steglatro contains the active ingredient ertugliflozin, used to treat type 2 diabetes in adults along with a good diet and exercise plan. Steglatro is not used to treat type 1 diabetes or diabetic ketoacidosis.

Steglatro lowers blood sugar and A1C levels by helping your kidneys to remove sugar when you urinate. Steglatro does this by blocking SGLT2 protein in the kidneys, halting the reabsorption of sugar back into the bloodstream. Although not a weigh loss drug, Steglatro may also cause mild weight loss.

You can buy Steglatro as 5mg or 15mg tablets. Patients are usually started with 5mg once per day first thing in the morning. If your blood sugar is not responding as required, you may be increased up to 15mg daily.

The active substance in Steglatro, ertugliflozin, helps to lower blood glucose by making the patient pass out glucose in the urine. It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.

Buy Steglatro from InsulinHub.com for the best Steglatro cost.

Information about Steglatro (Ertugliflozin)

Steglatro is an oral medication that contains ertugliflozin, which is a SGLT2 inhibitor (Sodium-Glucose Cotransporter-2 inhibitor). It is mainly used to treat type 2 diabetes by helping to lower blood sugar levels. Ertugliflozin works by preventing the reabsorption of glucose from the kidneys back into the bloodstream, allowing excess glucose to be excreted in the urine. Steglatro is usually combined with diet and exercise to help improve glycemic control in adults with type 2 diabetes. 

Product Highlights

• To help improve blood sugar control in adults with type 2 diabetes, typically when diet and exercise alone do not suffice.
• Steglatro is used alongside a balanced diet and regular exercise to help achieve and maintain desired blood glucose levels.
• It may be used alongside other medications like metformin, sulfonylureas, or insulin for better blood glucose management.

Key Ingredient

• Ertugliflozin

Key Benefits

• It works by lowering blood glucose levels through the excretion of glucose in the urine. 
• Steglatro may cause mild weight loss due to the glucose excretion process.
• When used alone, Steglatro has a lower risk of causing hypoglycemia (low blood sugar) compared to some other antidiabetic medications.
• Some SGLT2 inhibitors have been shown to offer cardiovascular protection, reducing the risk of heart failure and kidney disease in patients with type 2 diabetes.
• Steglatro is an oral medication, taken once daily, making it easier to integrate into daily routines.

Direction of Use

• The typical dose of Steglatro is 5 mg once daily. The dose may be increased to 15 mg once daily if needed. 
• Take Steglatro orally once a day, either with or without food. 
• Take the medication consistently at the same time each day for optimal results. 
• If you miss a dose, take it as soon as you recall, unless it's almost time for your next dose. Do not take two doses at once.

Safety Concerns

• Steglatro can increase urination, leading to dehydration. Staying hydrated by drinking plenty of fluids is essential. 
• Steglatro can affect kidney function. Kidney function should be checked both before and throughout the treatment. 
• SGLT2 inhibitors can increase the risk of urinary tract and genital fungal infections, especially in women. 
• Although rare, Steglatro can increase the risk of DKA, a serious condition characterized by high blood sugar and ketones in the blood.
• Steglatro may cause a decrease in blood pressure, particularly in patients who are dehydrated or have low blood pressure.
• Long-term use of SGLT2 inhibitors may increase the risk of bone fractures.
• There have been reports of increased risk of amputations, particularly of the toe, with SGLT2 inhibitors. Monitoring for signs of infection or poor circulation is important.

Avoid Steglatro (Ertugliflozin) If

• Steglatro is contraindicated in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²).
• If you have a known allergy to any component of Steglatro, you should not use it.
• Steglatro is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis (DKA). 
• The safety of Steglatro during pregnancy has not been determined. It should only be used if the potential benefits outweigh the risks. 
• It is unclear whether Steglatro is passed into breast milk. Consult with a healthcare provider before using Steglatro if you are breastfeeding.
• If you are dehydrated, you should not use Steglatro until your fluid balance is restored, as dehydration may increase the risk of side effects like low blood pressure or kidney problems.